Azora Therapeutics, Inc. (DE)
Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative colitis. Azora Therapeutics, Inc. was formerly known as Meya Pharmaceuticals, Inc. and changed its name to Azora Therapeutics, Inc. in March 2019. The company was incorporated in 2017 and is based in Encino, California.
No SEC Form 4 filings for $AZR in the last 30 days.
See all $AZR insider activity →Azora Therapeutics (AZR) reported Q3 GAAP EPS of -$4.52. Operating expenses increased to $7.53M from $1.76M, with R&D and G&A costs rising. Net loss widened to -$64.56M from -$1.79M year-over-year, according to the company.
Azora Therapeutics, Inc. (DE) (AZR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update Azora Therapeutics commenced trading on Nasdaq as “AZR” New executive team and Board of Directors appointed AT177 IND submission and Phase 1a initiation on track for the firs
Azora Therapeutics, Inc. (DE) (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Directors On November 3, 2026, each of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appoi
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AZR (Azora Therapeutics, Inc. (DE)). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent AZR coverage spans corporate actions, financial news and earnings.
Earnings miss and widening loss likely drive the stock lower.
The sizable quarterly loss and cash burn likely weigh on the stock, while the upcoming IND submission could provide a catalyst later in 2027.
Azora Therapeutics, Inc. (DE) (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Directors On November 3, 2026, each of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appoi
Board refresh adds experienced biotech executives, likely supporting execution and investor confidence.
Analyst initiation and target raise likely drive buying interest.
AlphAI scores every news story that mentions AZR with an AI model for sentiment and relevance, and aggregates insider trades from Azora Therapeutics, Inc. (DE)'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Azora Therapeutics (AZR) reported Q3 GAAP EPS of -$4.52. Operating expenses increased to $7.53M from $1.76M, with R&D and G&A costs rising. Net loss widened to -$64.56M from -$1.79M year-over-year, according to the company.
Azora Therapeutics, Inc. (DE) (AZR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update Azora Therapeutics commenced trading on Nasdaq as “AZR” New executive team and Board of Directors appointed AT177 IND submission and Phase 1a initiation on track for the firs
Azora Therapeutics, Inc. (DE) (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Directors On November 3, 2026, each of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appoi
Azora Therapeutics (AZR) has appointed a five-member board to advance its ulcerative colitis drug candidate, AT177, into clinical trials. The board includes executives with experience in drug development, financing, and governance. AT177 is designed to target colon inflammation and is planned for a Phase 1 trial in 2027. The company holds worldwide rights to its technology platform.
Jones Trading initiated coverage on Azora Therapeutics (AZR) with a Buy rating and a $14.00 price target. The stock trades at $3.81, with a 52-week range of $1.31 to $8.97. The company is developing AT177 for inflammatory bowel disease. Jones Trading estimates 28.5 million shares outstanding. AZR has surged 146% over the past six months despite year-to-date losses. TD Cowen also initiated coverage with a Buy rating, citing AT177's potential.
ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis Stockholders approved the conversion of the preferred stock issued in the June 2026 acquis
Adial Pharmaceuticals (ADIL) adjourned votes on Proposals 3–6 during its 2026 Annual Meeting, awaiting Nasdaq approval. The meeting will reconvene Oct. 26. Proposals 1,2,7-12 were voted on Sept. 17. The record date remains Aug. 17.
ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events As previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 18, 2026, on September 17, 2026, the Company convened its 2026 Annual Meetin
Adial Pharmaceuticals (NASDAQ:ADIL) appointed David Rubenstein, M.D., Ph.D. as Chief Scientist to lead research and development of AT177, a treatment for ulcerative colitis. Rubenstein previously led the FDA approval of tapinarof at Dermavant Sciences. AT177 is expected to begin first-in-human trials in 2027, according to the company.
Adial Pharmaceuticals (ADIL) adjourned votes on four proposals pending Nasdaq listing approval. The company held its 2026 Annual Meeting on Sept 17, voting on some proposals but delaying others. Votes on Proposals 3–6 were adjourned to Oct 1, then further delayed to Oct 15, 2026, due to outstanding Nasdaq approval. Shareholders who submitted proxies need not act unless changing their vote.
